Stryker Corporation $SYK Position Boosted by L. Roy Papp & Associates LLP

Key Points

• L. Roy Papp & Associates LLP increased its stake in Stryker Corporation by 1.2% to a total of 62,910 shares, making it the firm’s 9th largest holding with a value of approximately $24.89 million.
• Insider selling activities included Ronda E. Stryker, who sold 200,000 shares for over $75 million, reducing her ownership by 5.84%.
• Stryker recently announced a quarterly dividend of $0.84 per share, resulting in an annualized yield of 0.9% and a stated payout ratio of **44.5%**.

L. Roy Papp & Associates LLP raised its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 1.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,910 shares of the medical technology company's stock after acquiring an additional 726 shares during the quarter. Stryker makes up 3.0% of L. Roy Papp & Associates LLP's investment portfolio, making the stock its 9th largest holding. L. Roy Papp & Associates LLP's holdings in Stryker were worth $24,889,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Sachetta LLC grew its stake in Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock valued at $29,000 after acquiring an additional 27 shares in the last quarter. Goodman Advisory Group LLC purchased a new position in Stryker during the 1st quarter valued at about $32,000. Ridgewood Investments LLC grew its stake in Stryker by 48.4% during the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company's stock valued at $36,000 after acquiring an additional 30 shares in the last quarter. Ransom Advisory Ltd purchased a new position in Stryker during the 1st quarter valued at about $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in Stryker during the 1st quarter valued at about $40,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Viju Menon sold 500 shares of the company's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

SYK has been the topic of several research analyst reports. Truist Financial set a $415.00 target price on Stryker and gave the company a "hold" rating in a research note on Monday, August 4th. Wells Fargo & Company boosted their price target on Stryker from $435.00 to $445.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Rothschild & Co Redburn began coverage on Stryker in a research note on Thursday, September 18th. They issued a "neutral" rating and a $420.00 price target for the company. Weiss Ratings reissued a "buy (b-)" rating on shares of Stryker in a research note on Wednesday. Finally, Evercore ISI lowered their price target on Stryker from $418.00 to $410.00 and set an "outperform" rating for the company in a research note on Tuesday. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $430.10.

Stryker Stock Down 1.4%

SYK opened at $370.21 on Friday. The business has a 50 day moving average price of $380.53 and a 200 day moving average price of $378.80. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a market cap of $141.53 billion, a P/E ratio of 49.03, a price-to-earnings-growth ratio of 2.70 and a beta of 0.94.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same period in the previous year, the company earned $2.81 EPS. The company's revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker's payout ratio is 44.50%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.